2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P0184
    Camstatin 1002295-95-5 98%
    Camstatin, a functionally active 25-residue fragment of PEP-19's IQ motif, binds calmodulin and inhibits neuronal nitric oxide (NO) synthase.
    Camstatin
  • HY-P0192
    [Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2 213130-17-7 98%
    [Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2 is a nociceptin receptor (ORL1) agonist. [Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2 strongly depresses the nociceptive flexor reflex in rats. [Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2 can be used for analgesia research.
    [Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2
  • HY-P0193
    Nocistatin (Bovine) 208253-85-4 98%
    Nocistatin (Bovine) is a nociceptin precursor contains another biologically active peptide. Nocistatin (Bovine) blocks nociception-induced allodynia and hyperalgesia. Nocistatin (Bovine) also attenuates pain evoked by prostaglandin E2. Nocistatin (Bovine) can bind to the membrane of mouse brain and spinal cord with high affinity. Nocistatin (Bovine) can be studied in research on pain transmission.
    Nocistatin (Bovine)
  • HY-P0194
    NocII 188119-47-3 98%
    NocII is an orphan neuropeptide which stimulates locomotion in mice.
    NocII
  • HY-P0214
    Autocamtide-2-related inhibitory peptide 167114-91-2 98%
    Autocamtide-2-related inhibitory peptide is a highly specific and potent inhibitor of CaMKII with an IC50 of 40 nM.
    Autocamtide-2-related inhibitory peptide
  • HY-P0228
    PKA RII peptide 113873-67-9 98%
    PKA RII peptide is a PKA substrate that, after being phosphorylated at the serine residue, can be used for the detection of calcineurin activity.
    PKA RII peptide
  • HY-P1017
    MDL 29913 135721-56-1 98%
    MDL 29913, a cyclic pseudopeptide, is a competitive NK2 tachykinin receptor selective antagonist, with a pA2 of 8.66.
    MDL 29913
  • HY-P1020
    Nocistatin(human) 212609-11-5 98%
    Nocistatin (human) blocks nociceptin-induced allodynia and hyperalgesia, and attenuates pain evoked by prostaglandin E2.
    Nocistatin(human)
  • HY-P1051
    β-Amyloid (12-28) 107015-83-8 98%
    β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research.
    β-Amyloid (12-28)
  • HY-P1053
    β-Amyloid (10-20) 152286-31-2 98%
    β-Amyloid (10-20) is a fragment of Amyloid-β peptide and maybe used in the research of neurological disease.
    β-Amyloid (10-20)
  • HY-P1054
    pep2-EVKI 1315378-67-6 98%
    pep2-EVKI (YNVYGIEEVKI) is an inhibitor peptide that selectively blocks PICK1 interactions, caused the opposite effects on synaptic AMPAR function to PICK1 expression.
    pep2-EVKI
  • HY-P1055
    Pep2-SVKE 1315378-76-7 98%
    Pep2-SVKE is an inactive control peptide for pep2-SVKI (HY-P1056). Pep2-SVKE is an inhibitory peptide corresponding to the last 10 amino acids of the C-terminus of the GluR2 AMPA receptor subunit. Pep2-SVKE does not block AMPA-mediated [3H]DA exocytosis. Pep2-SVKE does not bind to GRIP or PICK43 and does not block retention of PICK1 by GST-GluR2 and LTD[1][2][3][4][5].
    Pep2-SVKE
  • HY-P1056
    pep2-SVKI 328944-75-8 98%
    pep2-SVKI is a selective peptide inhibitor. pep2-SVKI inhibits the binding of AMPA-type glutamate receptor (GluA2) (C-terminal PDZ site) to glutamate receptor interacting protein (GRIP), AMPA receptor binding protein (ABP), and C-kinase interacting protein (PICK1). pep2-SVKI increases the amplitude of AMPA receptor-mediated currents and blocks long-term depression (LTD). pep2-SVKI can be used to study neurological diseases.
    pep2-SVKI
  • HY-P1057
    Pep4c 243843-43-8 98%
    Pep4c is an inactive control peptide for Pep2m (HY-P1058). Pep4c lacks functional activity to disrupt Protein Interacting with C Kinase 1 (PICK1)-AMPA receptor (GluA2) or N-ethylmaleimide-sensitive factor (NSF)-GluA2 interactions. Pep4c is used as a negative control in experiments to validate the specificity of Pep2m's effects on AMPA receptor trafficking and synaptic plasticity[1][2][3][4][5][6].
    Pep4c
  • HY-P1058
    Pep2m 243843-42-7 98%
    Pep2m is a peptide receptor inhibitor. Pep2m inhibits the interaction between the C-terminus of the AMPA-type glutamate receptor (GluA2) subunit and N-ethylmaleimide-sensitive fusion protein (NSF). Pep2m prevents synaptic long-term depression (LTD). Pep2m can reduce postsynaptic currents in neurons, AMPA-mediated currents in cultured hippocampal neurons, and AMPA receptor surface expression[1][2][3][4][5].
    Pep2m
  • HY-P1059
    Pep2-AVKI 1315378-69-8 98%
    Pep2-AVKI is a selective peptide inhibitor of the binding of the AMPA receptor subunit (GluR2) at the C-terminal PDZ site to C-kinase (PICK1). Pep2-AVKI does not affect the binding of (AMPA-type glutamate receptor) GluA2 to GRIP or ABP. Pep2-AVKI does not increase the amplitude of AMPA currents. pep2-AVKI can be used to study neurological diseases.
    Pep2-AVKI
  • HY-P1060
    LPYFD-NH2 700361-48-4 98%
    LPYFD-NH2, a pentapeptide, exerts some inhibitory effect on the aggregation of Aβ(1-42). LPYFD-NH2 can be used for the research of Alzheimer’s disease.
    LPYFD-NH2
  • HY-P1078
    Huwentoxin XVI 1600543-88-1 98%
    Huwentoxin XVI, an analgesic, is a highly reversible and selective mammalian N-type calcium channel (IC50 of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels.
    Huwentoxin XVI
  • HY-P1080
    ω-Agatoxin IVA 145017-83-0 98%
    ω-Agatoxin IVA is a potent, selective P/Q type Ca2+ (Cav2.1) channel blocker with IC50s of 2 nM and 90 nM for P-type and Q-type Ca2+ channels, respectively. ω-Agatoxin IVA (IC50, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA also blocks the high potassium-induced release of serotonin and norepinephrine. ω-Agatoxin IVA has no effect on L-type or N-type calcium channels.
    ω-Agatoxin IVA
  • HY-P1114
    2B-(SP) 186901-17-7 98%
    2B-(SP) is a eIF2B-based substrate for glycogen synthase kinase-3 (GSK-3). 2B-(SP) is readily phosphorylated by both the α and β isoforms of GSK-3.
    2B-(SP)
Cat. No. Product Name / Synonyms Application Reactivity